Precigen Inc sold certain assets, including intellectual property rights related to the clinical product FCX-007, to Innovator 21, LLC for $8.5 million, and will use the proceeds for working capital. Following the sale, Precigen has no further rights or obligations regarding Castle Creek or the product.